Bi-modal dose-dependent cardiac response to tetrahydrobiopterin in pressure-overload induced hypertrophy and heart failure

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 564-569

  Moens, An L ^a   Ketner, Elizabeth A ^a   Takimoto, Eiki ^a   Schmidt, Tim S ^b   O'Neill, Charles A ^c   Wolin, Michael S ^d   Alp, Nicholas J ^b   Channon, Keith M ^b   Kass, David A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c BIOMARIN PHARMACEUTICAL INC   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Mouse models; Nitric oxide synthase; NOS uncoupling; Oxidative stress; Pressure overload; Tetrahydrobiopterin

Indexed keywords

DIHYDROBIOPTERIN; NITRIC OXIDE SYNTHASE; PLACEBO; SAPROPTERIN; TETRAHYDROBIOPTERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG PELLET; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; BIOPTERIN; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LIGATION; MICE; MICE, INBRED C57BL; MYOCARDIUM; RANDOM ALLOCATION; SUPEROXIDES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

MUS;

EID: 80052807512     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.05.017     Document Type: Article

References (33)

1. Moens A.L., Kass D.A. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. J Cardiovasc Pharmacol Sep 2007, 50(3):238-246.
2. Danks D.M., Cotton R.G., Schlesinger P. Letter: tetrahydrobiopterin treatment of variant form of phenylketonuria. Lancet Nov 22 1975, 2(7943):1043.
3. Levy H.L., Milanowski A., Chakrapani A., Cleary M., Lee P., Trefz F.K., et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet Aug 11 2007, 370(9586):504-510.
4. Kwon N.S., Nathan C.F., Stuehr D.J. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem Dec 5 1989, 264(34):20496-20501.
5. Vasquez-Vivar J. Tetrahydrobiopterin, superoxide, and vascular dysfunction. Free Radic Biol Med Oct 15 2009, 47(8):1108-1119.
6. Kotsonis P., Frohlich L.G., Shutenko Z.V., Horejsi R., Pfleiderer W., Schmidt H.H. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochem J Mar 15 2000, 346(Pt 3):767-776.
7. Landmesser U., Merten R., Spiekermann S., Buttner K., Drexler H., Hornig B. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation May 16 2000, 2264-2270. Sect.
8. Schulz E., Jansen T., Wenzel P., Daiber A., Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal Jun 2008, 10(6):1115-1126.
9. Shinozaki K., Kashiwagi A., Nishio Y., Okamura T., Yoshida Y., Masada M., et al. Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2-imbalance in insulin-resistant rat aorta. Diabetes Dec 1999, 48(12):2437-2445.
10. Sasaki N., Yamashita T., Takaya T., Shinohara M., Shiraki R., Takeda M., et al. Augmentation of vascular remodeling by uncoupled endothelial nitric oxide synthase in a mouse model of diabetes mellitus. Arterioscler Thromb Vasc Biol Jun 2008, 28(6):1068-1076.
11. Wu G., Meininger C.J. Nitric oxide and vascular insulin resistance. Biofactors Jan-Feb 2009, 35(1):21-27.
12. Cosentino F., Hurlimann D., Delli Gatti C., Chenevard R., Blau N., Alp N.J., et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart Apr 2008, 94(4):487-492.
13. Tiefenbacher C.P., Bleeke T., Vahl C., Amann K., Vogt A., Kubler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation Oct 31 2000, 102(18):2172-2179.
14. Yang Y.M., Huang A., Kaley G., Sun D. eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol Nov 2009, 297(5):H1829-H1836.
15. Pieper G.M., Ionova I.A., Cooley B.C., Migrino R.Q., Khanna A.K., Whitsett J., et al. Sepiapterin decreases acute rejection and apoptosis in cardiac transplants independently of changes in nitric oxide and inducible nitric-oxide synthase dimerization. J Pharmacol Exp Ther Jun 2009, 329(3):890-899.
16. Takimoto E., Champion H.C., Li M., Ren S., Rodriguez E.R., Tavazzi B., et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest May 2005, 115(5):1221-1231.
17. Settergren M., Bohm F., Malmstrom R.E., Channon K.M., Pernow J. L-arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease. Atherosclerosis May 2009, 204(1):73-78.
18. Dumitrescu C., Biondi R., Xia Y., Cardounel A.J., Druhan L.J., Ambrosio G., et al. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc Natl Acad Sci USA Sep 18 2007, 104(38):15081-15086.
19. Worthley M.I., Kanani R.S., Sun Y.H., Sun Y., Goodhart D.M., Curtis M.J., et al. Effects of tetrahydrobiopterin on coronary vascular reactivity in atherosclerotic human coronary arteries. Cardiovasc Res Dec 1 2007, 76(3):539-546.
20. Moens A.L., Takimoto E., Tocchetti C.G., Chakir K., Bedja D., Cormaci G., et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation May 20 2008, 117(20):2626-2636.
21. Gao L., Pung Y.F., Zhang J., Chen P., Wang T., Li M., et al. Sepiapterin reductase regulation of endothelial tetrahydrobiopterin and nitric oxide bioavailability. Am J Physiol Heart Circ Physiol Jul 2009, 297(1):H331-H339.
22. Du Y.H., Guan Y.Y., Alp N.J., Channon K.M., Chen A.F. Endothelium-specific GTP cyclohydrolase I overexpression attenuates blood pressure progression in salt-sensitive low-renin hypertension. Circulation Feb 26 2008, 117(8):1045-1054.
23. Alp N.J., Mussa S., Khoo J., Cai S., Guzik T., Jefferson A., et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J Clin Invest Sep 2003, 112(5):725-735.
24. Silberman G.A., Fan T.H., Liu H., Jiao Z., Xiao H.D., Lovelock J.D., et al. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation Feb 2 2010, 121(4):519-528.
25. Fiege B., Ballhausen D., Kierat L., Leimbacher W., Goriounov D., Schircks B., et al. Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol Genet Metab Jan 2004, 81(1):45-51.
26. Sugiyama T., Levy B.D., Michel T. Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells. J Biol Chem May 8 2009, 284(19):12691-12700.
27. Crabtree M.J., Tatham A.L., Hale A.B., Alp N.J., Channon K.M. Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways. J Biol Chem Oct 9 2009, 284(41):28128-28136.
28. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med Feb 2005, 11(2):214-222.
29. Heineke J., Auger-Messier M., Xu J., Oka T., Sargent M.A., York A., et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest Nov 2007, 117(11):3198-3210.
30. Gorren A.C., Bec N., Schrammel A., Werner E.R., Lange R., Mayer B. Low-temperature optical absorption spectra suggest a redox role for tetrahydrobiopterin in both steps of nitric oxide synthase catalysis. Biochemistry Sep 26 2000, 39(38):11763-11770.
31. Crabtree M.J., Smith C.L., Lam G., Goligorsky M.S., Gross S.S. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am J Physiol Heart Circ Physiol Apr 2008, 294(4):H1530-H1540.
32. Takeda M., Yamashita T., Shinohara M., Sasaki N., Takaya T., Nakajima K., et al. Plasma tetrahydrobiopterin/dihydrobiopterin ratio: a possible marker of endothelial dysfunction. Circ J May 2009, 73(5):955-962.
33. Porkert M., Sher S., Reddy U., Cheema F., Niessner C., Kolm P., et al. Tetrahydrobiopterin: a novel antihypertensive therapy. J Hum Hypertens Jun 2008, 22(6):401-407.